Investors should skip buying Merck shares because of valuation and political risk, BMO Capital said. » Read More
U.S. stocks closed lower Wednesday in low volume trade as a decline in oil prices weighed.
The latest drug-price increases are just the tip of the iceberg, explains former Medtronic CEO Bill George.
The Fed's decision Wednesday to increase interest rates for the first time since June 2006 sparked a rally in an unlikely group of stocks.
U.S. stocks closed higher after the Federal Reserve raised rates for the first time in nearly a decade. Only the energy sector lagged as oil prices resumed their decline.
Some of the names on the move ahead of the open.
U.S. stock futures were sharply higher this morning, after Monday's strong gains on Wall Street.
The "Fast Money" traders give their final trades of the day.
U.S. stocks closed lower, weighed by a sharp decline in energy as oil plunged to a near-seven-year low.
The U.S. is at a disadvantage because of this, two health-care CEOs said.
U.S. stocks closed sharply lower as yields climbed and traders were worried the Fed would raise rates while the economy is too weak.
The "Halftime Report" traders give their top trades of the show.
U.S. stocks closed lower as investors eyed retail results and readied for key data and central bank comments later in the week.
U.S. stocks closed mostly higher, as gains in oil prices and energy stocks helped offset an earlier decline following news of a downed Russian jet.
U.S. stocks closed more than 1 percent lower, pressured by a continued decline in oil prices and soft reports on the health of the consumer.
European equities finished sharply lower on Thursday, as oil prices and a fall in Rolls-Royce shares dented investor sentiment.
Jim Cramer rattles off his take on caller favorite stocks, including this stock that is down so low it is ridiculous.
Millennials invest less in the stock market than baby boomers do — and when they do, they're favoring very different stocks.
U.S. stocks closed lower, after a solid start to November, weighed by a decline in energy and more confidence in the possibility of a December hike.
Bone replacements, human tissue and prosthetics are being created by 3-D bioprinters. The science will soon be used to customize drugs.
These stocks are falling behind the S&P 500, and one technician says the underperformance is starting to look like 2000 and 2007.